Skip to content
drillr.ai
Sign up

GANX

Gain Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.25
−0.79%
Ask drillr

  • Oct 1, 2026, 13:28 UTC

    Gain Therapeutics presented positive Phase 1b open-label extension data for rexaceract, showing stable MDS-UPDRS motor scores and no disease progression in 12 evaluable participants who completed 12 months of daily oral administration by August 31, 2026.

    Source:

  • Sep 28, 2026, 20:38 UTC

    Gain Therapeutics, Inc. Senior Vice President of Finance and principal financial and accounting officer Gianluca Fuggetta resigned effective September 30, 2026.

  • Sep 28, 2026, 20:38 UTC

    Gain Therapeutics, Inc. appointed Gene Mack as interim Chief Financial Officer effective October 1, 2026.